Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.

Abstract

OBJECTIVE To assess morbidity in patients with severe sepsis managed with and without drotrecogin alfa (activated). DESIGN Analysis of secondary end points in a prospective, randomized, double-blind, placebo-controlled, multicenter, phase 3 trial (PROWESS). SETTING A total of 164 medical institutions in 11 countries. PATIENTS A total of 1,690… (More)

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics